EmbryoNet-AI
EmbryoNet-AI
Agent21Agent Readiness: 21/100. Bottom 25%. Measured by StartupHub.ai. Median 41.AI platform for embryonic phenotyping that accelerates drug discovery and toxicology testing by automating analysis of embryos and organoids.
About
EmbryoNet-AI is an ERC-funded research-to-commercialization project developing deep learning models for automated embryonic and organoid phenotyping. The platform enables faster, more accurate assessment of compound effects in drug discovery and toxicology studies, reducing dependence on animal models. The project is building a user-friendly web interface and collaborating with pharma partners to commercialize the technology.
Key facts
At-a-glance profile data
- Website
- embryonet.de
- Headquarters
- Lisbon, Portugal
- Founded
- 2025
- Total funding
- $150K (Grant)
- Business model
- B2B
Add first review
Frequently asked
How much funding has EmbryoNet-AI raised?
EmbryoNet-AI has raised a total of $150K in funding. The most recent round on record is Grant.